1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics, September 2019

Healthcare Analysis & Statistics, September 2019

Customer Support

Talk to Veronica

+1 718 514 2762

Publishers

  • All
    • Cancer Research Analytics

data types

1-13 of 13 reports

Oncology Drug Report: Zydelig | Idelalisib – 2011 -2016 analysis; 2017-2021 expectations

Oncology Drug Report: Zydelig | Idelalisib – 2011 -2016 analysis; 2017-2021 expectations

  • $ 308
  • Industry report
  • January 2017

Zydelig (idelalsib): strong start but not expected to continue” is a comprehensive report on the first-in-class, targeted, oral PI3K delta inhibitor approved drug for relapsed chronic lymphocytic leukemia ...

  • Industries : Therapy, Cancer, Pathology, Medical Biotechnology, Oncology
  • Countries : United States
Gardasil | human papillomavirus vaccine - Oncology drug report: 2006-2016 analysis, 2017-2021 expectations

Gardasil | human papillomavirus vaccine - Oncology drug report: 2006-2016 analysis, 2017-2021 expectations

  • $ 308
  • Industry report
  • January 2017

“Gardasil: star cancer vaccine” is a comprehensive drug report on the market leader of HPV vaccine segment (according to 2015 sales).In this report, Gardasil and Gardasil 9 are considered as a single ...

  • Industries : Therapy, Pathology, Pharmaceutical
  • Countries : United States, North America
Oncology drug report - Kadcyla - ado-trastuzumab emtansine - 2013-2015 analysis; 2016-2021 expectations

Oncology drug report - Kadcyla - ado-trastuzumab emtansine - 2013-2015 analysis; 2016-2021 expectations

  • $ 308
  • Industry report
  • December 2016

“Kadcyla (ado-trastuzumab emtansine): Armed antibody” is a comprehensive report on the first USFDA approved drug with antibody–drug conjugate for HER2-positive metastatic breast cancer treatment.Kadcyla ...

  • Industries : Therapy, Oncology
  • Countries : United States, North America
Iressa - gefitinib -Oncology drug report -  2002-2015 analysis; 2016-2021 expectations

Iressa - gefitinib -Oncology drug report - 2002-2015 analysis; 2016-2021 expectations

  • $ 308
  • Industry report
  • December 2016

“Iressa: on a downward spiral” is a comprehensive drug report about the first EGFR tyrosine kinase inhibitor drug in the NSCLC market.Iressa is the first drug in the EGFR-TKI market to be approved ...

  • Industries : Therapy, Pharmaceutical
  • Countries : United States
Oncology drug report - Vidaza - azacitidine - 2004-2015 analysis; 2016-2021 expectations

Oncology drug report - Vidaza - azacitidine - 2004-2015 analysis; 2016-2021 expectations

  • $ 308
  • Industry report
  • December 2016

Vidaza: Top drug losing sheen” is a comprehensive drug report on the largest drug in the MDS space that seems to be falling apart post its patent expiry.Vidaza is the fourth-largest drug in Celgene’s ...

  • Industries : Drug Development, Pharmaceutical, Cancer, Pathology
  • Countries : United States, North America, Japan
Oncology drug report - Perjeta - pertuzumab - 2012-2015 analysis; 2016-2021 expectations

Oncology drug report - Perjeta - pertuzumab - 2012-2015 analysis; 2016-2021 expectations

  • $ 308
  • Industry report
  • December 2016

“Perjeta (pertuzumab): In the spotlight” is a comprehensive report on the first and only USFDA approved drug for eoadjuvant breast cancer treatment.Perjeta falls in the monoclonal antibody, HER2 dimerization ...

  • Industries : Therapy, Oncology
  • Countries : United States, North America
Oncology drug report - Pomalyst - Pomalidomide - 2013-2015 analysis; 2016-2021 expectations

Oncology drug report - Pomalyst - Pomalidomide - 2013-2015 analysis; 2016-2021 expectations

  • $ 308
  • Industry report
  • December 2016

“Pomalyst: maintaining the legacy - 2013-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the market leader of third line treatment in multiple myeloma (according to 2015 s ...

  • Industries : Therapy, Oncology
  • Countries : United States
Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations

Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations

  • $ 308
  • Industry report
  • December 2016

“Iclusig - ponatinib - Oncology drug report - 2013-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the most controversial drug in recent times. Iclusig is the first and only ...

  • Industries : Pharmaceutical, Therapy, Drug Development
  • Countries : United States, North America
Oncology drug report - Xalkori - crizotinib - 2011-2015 analysis; 2016-2021 expectations

Oncology drug report - Xalkori - crizotinib - 2011-2015 analysis; 2016-2021 expectations

  • $ 308
  • Industry report
  • December 2016

Xalkori: Strong start but competition ahead” is a comprehensive drug report about the market leader in ALK-positive metastatic NSCLC called Xalkori.Xalkori is the third-largest drug in Pfizer’s portfolio ...

  • Industries : Therapy, Cancer, Pathology, Drug Development, Pharmaceutical, Oncology
  • Countries : United States
Oncology drug report - Herceptin - trastuzumab - 2006-2015 analysis; 2016-2021 expectations

Oncology drug report - Herceptin - trastuzumab - 2006-2015 analysis; 2016-2021 expectations

  • $ 308
  • Industry report
  • November 2016

“Herceptin (trastuzumab): 2006-2015 analysis; 2016-2021 expectations” is a comprehensive report on the second-largest oncology drug by 2015 sales.Herceptin falls in the monoclonal antibody, HER2 inhibitor, ...

  • Industries : Therapy, Pharmaceutical, Medical Biotechnology, Oncology, Biopharmaceutical, Biopharmaceutical, Drug Development
  • Countries : United States, North America
Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations

  • $ 513
  • Industry report
  • November 2016

Description“Oncology drug report - Revlimid - lenalidomide - 2005-2015 analysis; 2016-2021 expectations” is a comprehensive drug report on the fouth-largest oncology drug by 2015 sales. Revlimid is ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States
Oncology drug report - Votrient - pazopanib - 2009-2015 analysis; 2016-2021 expectations

Oncology drug report - Votrient - pazopanib - 2009-2015 analysis; 2016-2021 expectations

  • $ 513
  • Industry report
  • November 2016

Description“Oncology drug report - Votrient - pazopanib - 2009-2015 analysis; 2016-2021 expectations” is a comprehensive report on multi-tyrosine kinase inhibitor targeted therapy drug Votrient’s ...

  • Industries : Cancer, Therapy, Pathology, Pharmaceutical, Drug Development, Oncology
  • Countries : United States
Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

Oncology drug report - Adcetris - brentuximab vedotin - 2011-2015 analysis; 2016-2021 expectations

  • $ 513
  • Industry report
  • November 2016

“Adcetris: 2011-2015 analysis; 2016-2021 expectations” is a comprehensive report on the first and only approved drug of Seattle Genetics called Adcetris, which is also the first drug approved by the ...

  • Industries : Therapy, Cancer, Pharmaceutical, Oncology, Pathology, Medical Biotechnology, Drug Development, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, North America


About 283000 reports

Download Unlimited Documents from Trusted Public Sources

Type 2 Diabetes Statistics in the US

  • September 2019
    13 pages
  • Type 2 Diabetes  

    Diabetes  

  • United States  

    India  

View report >

HIV AIDS Statistics September 2019


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on